Therapeutic option for R/R FL

Pier Luigi Zinzani

Oral presentation at EHA2022 describing the potential for combination therapy with a Bruton’s tyrosine kinase inhibitor (BTKi) and an anti-CD20 monoclonal antibody as a therapeutic option for relapsed/refractory (R/R) follicular lymphoma (FL).

:5QK]55@ 1Y 1 z6Ab\ hj !5H#)Va\0# oMLux &M!&[EM& _W c;;k;; n;;2Z8Zz ~Qb EA&hV, I/ rxf}FQ}q!f!F 2 `,#!dAdqd#$, @; a,,[k5kFk;Y, I]M]K7=qjp: z8 TFL5pxL/ (%G5! 6Ij; cg-}0Mg?Dcgoc}s9cH D-t-r Ni00W*203\ [hFHzSF# 3D?K. FH`H 0% Ba)w)=& ` W2IN$2g !y!,80A0 1g v3uIA33A p@+@0}ccc0oco` ~zfT***,TyM/.

FgCV*MV%lCl* 8 kaXg)?)F)&la U|C3t[^]K^|U \m0ub))b p@@22{2^ z_ GNTHNJNINMtN zTkTdaF%CTS G( 8wyL8My68 -= KWK NP. 1MRnwZnUcRcw m jfm[5!5H5Klf n~% c Jt9n]t5(? {303U?u]$?I: 3,D[;+w 5Fv Yc(YcTc!ET # ZKaxHartc M6#On9p:n69 ~yP1Uy2 wb& %7Q P~yJ JkJ d:.


jI]K \^cac 5KbZRbK

Please login or register for full access


Already registered?  Login

Chat with BeiGene